FY2029 Earnings Estimate for VIGL Issued By Wedbush

Vigil Neuroscience, Inc. (NASDAQ:VIGL) – Equities research analysts at Wedbush issued their FY2029 earnings per share estimates for shares of Vigil Neuroscience in a report issued on Thursday, March 13th. Wedbush analyst L. Chico expects that the company will post earnings of $1.40 per share for the year. Wedbush currently has a “Outperform” rating and a $13.00 target price on the stock. The consensus estimate for Vigil Neuroscience’s current full-year earnings is ($2.07) per share.

A number of other equities research analysts have also issued reports on the company. JMP Securities reissued a “market outperform” rating and set a $22.00 price target on shares of Vigil Neuroscience in a research note on Tuesday, November 26th. HC Wainwright lowered their target price on shares of Vigil Neuroscience from $17.00 to $14.00 and set a “buy” rating for the company in a research note on Friday. Guggenheim reaffirmed a “buy” rating on shares of Vigil Neuroscience in a research note on Friday, January 24th. Finally, William Blair began coverage on shares of Vigil Neuroscience in a research report on Wednesday, December 4th. They issued an “outperform” rating for the company. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $16.25.

Vigil Neuroscience Price Performance

Shares of NASDAQ VIGL opened at $2.02 on Monday. Vigil Neuroscience has a 1 year low of $1.49 and a 1 year high of $6.06. The firm has a 50-day simple moving average of $2.34 and a two-hundred day simple moving average of $2.78. The company has a market cap of $82.58 million, a P/E ratio of -0.98 and a beta of 1.82.

Vigil Neuroscience (NASDAQ:VIGL) last announced its earnings results on Thursday, March 13th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.08).

Institutional Trading of Vigil Neuroscience

Hedge funds have recently added to or reduced their stakes in the business. Woodline Partners LP increased its position in Vigil Neuroscience by 239.1% during the 4th quarter. Woodline Partners LP now owns 488,756 shares of the company’s stock valued at $831,000 after purchasing an additional 344,614 shares during the period. Squarepoint Ops LLC purchased a new position in Vigil Neuroscience during the fourth quarter valued at approximately $193,000. Two Sigma Advisers LP raised its stake in Vigil Neuroscience by 243.8% in the fourth quarter. Two Sigma Advisers LP now owns 69,100 shares of the company’s stock worth $117,000 after buying an additional 49,000 shares in the last quarter. Two Sigma Investments LP lifted its holdings in Vigil Neuroscience by 44.0% during the fourth quarter. Two Sigma Investments LP now owns 136,920 shares of the company’s stock worth $233,000 after buying an additional 41,836 shares during the period. Finally, Trustees of Columbia University in the City of New York bought a new stake in Vigil Neuroscience during the 4th quarter valued at $328,000. 83.64% of the stock is owned by hedge funds and other institutional investors.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.